Monopar Therapeutics stock trades near $92.46 support amid ongoing pullback
Monopar Therapeutics (MNPR) stock is trading at $97.14, registering a sharp daily decline of 5.27%. The price currently sits below its short- and medium-term moving averages, while holding above levels associated with its longer-term trend.
68.2200
74.8000
Highlights
- MNPR/USD trades below short- and medium-term moving averages, showing ongoing downside pressure in the short term.
- Momentum and volatility readings reflect seller dominance, with a 5.27% loss to $97.14 and high intraday volatility.
- MNPR/USD is expected to move within the $92.46 to $101.82 range, with a significant drop highly probable if support is breached.
Bearish momentum prevails as technical signals turn mixed
MNPR is below the MA-20 at $102.63 and the MA-50 at $107.54 on the hourly chart, while still trading above the MA-200 at $75.97 on the daily timeframe. The Ichimoku Kijun sits at $104.59, marking a nearby resistance. Momentum indicators show a strong bearish alignment, with MACD at Strong Sell and ADX at Sell. RSI reads 43.61, reflecting a selling bias, while Stochastic RSI is Overbought and the Commodity Channel Index is Neutral; Bull/Bear Power remains Oversold, and Awesome Oscillator is Neutral, leaving signals of exhaustion and direction mixed.
Downside risk elevated as volatility defines fluctuating range
Over the coming sessions, MNPR is likely to fluctuate within the $92.46 to $101.82 range as defined by recent volatility. The probability of a further drop remains high, while a reversal higher is considered unlikely in the short term. A breakout above the $104.59 resistance would be needed to shift the outlook bullish, but if $92.46 support is breached, further downside acceleration could follow.
Earlier, analysts noted that Monopar Therapeutics faced heightened downside risk amid persistent negative momentum and weakening technical structure. The latest developments reinforce this bearish scenario, with increased volatility and the $92.46 support now emerging as a crucial level for potential further declines.
Latest Monopar Therapeutics News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
